Anti-Human CTLA-4 (Ipilimumab) - HRP Biosimilar (IVMB0454)
- SKU:
- IVMB0454
- Antibody Type:
- HRP Biosimilar
- Modifications:
- HRP-Conjugated
- Applications:
- IHC
- FC
- ELISA
- Drug Development
- Inflammatory Response Assays
- Pharmacokinetics
- Disease Area:
- Cancer Immunotherapy
- Disease Area:
- Autoimmune Diseases
Description
| Product Name: | Anti-Human CTLA-4 (Ipilimumab) - HRP |
| SKU: | IVMB0454 |
| Size: | 100 µg |
| Antibody Type: | Biosimilar Recombinant Human Monoclonal Antibody |
| Clone: | MDX-010 |
| Target: | CTLA-4 |
| Isotype: | Human IgG1κ |
| Host Species: | Human |
| Reactivity: | Human |
| Applications: | ELISA |
| Expression Host: | HEK-293 Cells |
| FC Effector Activity: | Active |
| Synonyms: | CD; GSE; GRD4; ALPS5; CD152; CTLA-4; IDDM12; CELIAC3 |
| Product Concentration: | 0.5 mg/ml |
| Immunogen: | Human CTLA-4 |
| Applications and Recommended Usage: | FC The suggested concentration for Ipilimumab biosimilar antibody for staining cells in flow cytometry is ≤ 1.0 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application. ELISA |
| Antigen Distribution: | CTLA4 is constitutively expressed in regulatory T cells. |
| Formulation: | This HRP-conjugated antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4, 1% BSA. (Warning: Use of sodium azide as a preservative will inhibit the enzyme activity of horseradish peroxidase) |
| Specificity: | This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Ipilimumab. Ipilimumab binds to Human CTLA-4. This product is for research use only. |
| Additional Reported Applications For Relevant Conjugates: | BCyTOF |
Cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) is a protein receptor that serves as an immune checkpoint and down-regulates the immune system. CTLA-4 is constitutively expressed in regulatory T cells but is only upregulated in conventional T cells following activation. Many cancers, including Melanoma, are associated with CTLA-4 upregulation because the body’s ability to recognize and destroy cancer cells is hampered by an inhibitory mechanism. Ipilimumab targets CTLA-4 and works by turning off this inhibitory mechanism and, thus, enhances the body’s own immune response against cancer cells.”2 Emerging research suggests that combined blockade of PD-1 and CTLA-4, with Nivolumab and Ipilimumab respectively, could produce greater antitumor activity than blockade of either pathway alone.1 This cost-effective, research-grade Anti-Human CTLA-4 (Ipilimumab) utilizes the same variable regions from the therapeutic antibody Ipilimumab making it ideal for research projects.
| Regulatory Status: | Research Use Only (RUO). Non-Therapeutic. |
| Storage and Handling: | This horseradish peroxidase conjugated monoclonal antibody is stable when stored at 2-8°C.Do not freeze. |
| Research Area: | Biosimilars |
Related Products
Anti-Human CTLA-4 (Ipilimumab) - Fc Reduced HRP Biosimilar (IVMB0456)
Anti-Human CTLA-4 (Ipilimumab) - Biotin Biosimilar (IVMB0453)
ipilimumab Biosimilar (Anti-CTLA-4) Antibody (HDBS0022)
VivoGenie Anti-CTLA-4 (Ipilimumab) Biosimilar (IVMB0217)
